【数据支撑】目前，Arexvy已获美国批准用于预防60岁及以上成年人中RSV相关疾病，同时也适用于50至59岁具有风险因素的成人。此次新申请主要针对年龄段在50岁以下但存在高风险因素的人群。美国FDA预计将在2026年上半年针对该申请做出决策，同时欧 ...

Investing.com - Brookline Capital Markets重申Moderna (NASDAQ: MRNA ...

Investing.com -- 在美国食品药品监督管理局（FDA）批准其COVID-19疫苗Spikevax用于6个月至11岁且COVID-19疾病风险增加的儿童后，Moderna Inc (NASDAQ: MRNA )股价上涨4.4%。

智通财经APP获悉，辉瑞(PFE.US)及其新冠疫苗Comirnaty的合作伙伴BioNTech(BNTX.US)周四向伦敦上诉法院提交法律文件，试图推翻此前法院作出的有利于竞争对手Moderna(MRNA.US)的专利胜诉裁决。两家公司希望推翻高等 ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...

周二，美股医药板块股票走高，截至发稿，Moderna (MRNA.US)涨超9%，礼来 (LLY.US)涨超2%，诺和诺德 (NVO.US)涨超1.4%，辉瑞 (PFE.US)涨超2%，联合健康 (UNH.US)涨0.89%。消息面上，Moderna近期公布了其mRNA流感疫苗候选产品mRNA-1010的三期临床试验 ...

The FDA action comes weeks after US Health Secretary Robert F. Kennedy Jr said the government would no longer recommend the COVID vaccine for healthy children or pregnant people.

Firms like Moderna that are rapidly adopting AI and will have a higher mix of AI software robots to humans in the future ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...